Abstract: A genetically-modified rat having a PKHD1L1 gene with a point or other mutation and a construction method thereof are disclosed. A CRISPR/Cas9 system knocks the PKHD1L1 gene into a mouse source, and a codon changes from TTA to TCA to construct the mutant PKHD1L1 gene. The genetically-modified rat can be applied to epilepsy pathogenesis studies and design and testing of new anti-epileptic drugs. Methods for detecting abnormal cortical excitability and detecting an epileptic phenotype of an animal can use the genetically-modified rat. A somatosensory evoked potential is used to detect whether the genetically-modified rat has an abnormal cortical excitability phenotype, so as to confirm whether the rat can be a successful model for testing anti-epileptic drugs. The method can detect abnormal cortical excitability and verify the effectiveness of anti-epileptic drugs or treatments.

Abstract: Disclosed are the methods for the detection and/or quantification of an analyte in liquid sample. The same principle can be applied in the case of detection and/or quantification of more than one analyte present in the sample. Devices of the invention include a sample application zone, a mobilization zone containing a mobile or mobilizable first binder that is specific for the analyte, a absorption zone containing immobilized analyte or analyte analog, a mobilization zone containing a mobile or mobilizable labeled second binder capable of binding to the first binder, and a capture zone or test zone containing an immobilized third binder capable of binding to the complex of the analyte, the first binder and the second binder. The color development in the capture zone or the test zone is indicative of presence or the concentration of the analyte in the test sample.